Coverage of the top Medical companies.
Plans to File PMA Application and Bring Product to the US DURHAM, NC – December 14, 2016 – Bioventus, a global leader in orthobiologic solutions, today announced it has a new agreement with Galderma for DUROLANE, a single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. […]
November 17, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the […]
GSK announces new data from phase III studies of sirukumab in adult patients with moderately to severely active rheumatoid arthritis
London – 16 November 2016 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced results from two pivotal phase III studies evaluating subcutaneous sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). The first study (SIRROUND-T), in patients who were refractory to or intolerant to […]
Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 16, 2016– Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations, with responsibility for commercial operations in North America, Europe and Japan. Mr. Meyers will become an officer of the company and member of Gilead’s senior leadership team. Mr. Meyers […]
Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers
Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations November 14, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). As part […]
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed November 13, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three […]
Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib) Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen
Patients Taking Pfizer’s Celebrex (celecoxib) Experienced Fewer Gastrointestinal Events As Compared to Prescription Doses of Ibuprofen and Naproxen Study Findings Dispel Long Standing Perceptions of Excess Cardiovascular Risk Associated With Long Term Use Of Celebrex Results of PRECISION Study Presented at the Annual Meeting of the American Heart Association in New Orleans Provide Important Information […]
Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities
Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® November 12, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the […]
Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
First seven participants, through a combined 103 weeks of observation as of Aug. 4, 2016, did not need infusions of factor IX concentrates to prevent bleeding Updated SPK-9001 data in hemophilia B to be presented at the Plenary Scientific Session at 58th American Society of Hematology Annual Meeting November 3, 2016 – PHILADELPHIA and NEW […]
Exclusive Platform Provides a Single Source to Analyze Online Patient Feedback and Comments BOSTON — OCT 27, 2016 –(BUSINESS WIRE)– Press Ganey today announced the introduction of the Press Ganey ® Consumer Analytics Solution , designed to help health care organizations monitor and analyze patient feedback across a variety of consumer-facing sources. Powerful analytics across […]
March 20, 2017 @ 8:00 am – March 25, 2017 @ 5:00 pm
Join us at the 95th General Session & Exhibition of the IADR, held in conjunction with the 46th Annual meeting of AADR and the 41st Annual Meeting of the CADR, occurring March 22-25, 2017, at the Moscone West Convention Center in San Francisco, Calif, USA.
March 24, 2017 @ 8:00 am – March 27, 2017 @ 5:00 pm
APhA2017 is the most comprehensive and well-respected pharmacy meeting for pharmacy professionals and future leaders in pharmacy. APhA2017 delivers presentations by nationally recognized experts covering topics ranging from leadership and pharmacy management to patient safety and medication errors.
March 26, 2017 @ 9:00 am – March 29, 2017 @ 5:00 pm
Make plans now to join us in Boston for the PLRB 2017 Claims Conference, the largest and most diverse educational conference in our industry. You’ll network with top claim professionals from hundreds of insurance companies, along with service providers from every part of our nation.
March 30, 2017 @ 9:00 am – April 2, 2017 @ 5:00 pm
By joining the International Vision Expo & Conference community, you gain the most direct path to becoming Visionary in your own right. Twice a year, once in New York City and once in Las Vegas the global eyecare community comes together for two unique events focused on Education, fashion and technology.